A Phase 1, Repeated-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750 mg Bid Administered to Patients With Impaired Hepatic Function Compared to Matching Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2011
At a glance
- Drugs Naproxcinod (Primary)
- Indications Osteoarthritis
- Focus Pharmacokinetics
- Sponsors NicOx
- 12 Mar 2008 New trial record.